ResearcherUniversity of Virginia Health SystemActive in the last 2 years
Timothy N. J. Bullock
Matched on ORCID iD 0000-0001-6141-3261; OpenAlex author ID A5082340810, A5108498427. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- Focused ultrasound as a therapeutic adjunct in pancreatic cancer: from thermal and mechanical effects to immune modulation. Co-author DOI 10.14366/usg.25199↗
- Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model. Last author DOI 10.1109/tbme.2025.3568594↗
- Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma. Last author DOI 10.3389/fcell.2023.1173686↗
- CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2283↗
- Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.23944↗
- A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT… Co-author DOI 10.1186/2051-1426-3-s2-p167↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Awndre Gamache · 2 shared papers, 2023–2025 · strength 0.47
- Todd W. Bauer · 3 shared papers, 2018–2023 · strength 0.37
- Paper Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma. DOI 10.3389/fcell.2023.1173686↗
- Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. DOI 10.18632/oncotarget.23944↗
- Paper CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-17-2283↗
- Chrit T. W. Moonen · 1 shared paper, 2026 · strength 0.29
- Jae Young Lee · 1 shared paper, 2026 · strength 0.29
- Joan Vidal-Jové · 1 shared paper, 2026 · strength 0.29
- Holger Grüll · 1 shared paper, 2026 · strength 0.29
- Petros Mouratidis · 1 shared paper, 2026 · strength 0.29
- Cyril Lafon · 1 shared paper, 2026 · strength 0.29
- Mariia Stepanechko · 1 shared paper, 2025 · strength 0.26
- Craig Lee Slingluff · 3 shared papers, 2015–2018 · strength 0.20
- Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. DOI 10.18632/oncotarget.23944↗
- Paper CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-17-2283↗
- Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
- Kiley L. Anderson-Knapp · 1 shared paper, 2018 · strength 0.08
- John C. Herr · 1 shared paper, 2018 · strength 0.08
- Alex D. Michaels · 1 shared paper, 2018 · strength 0.07
- Timothy Eric Newhook · 1 shared paper, 2018 · strength 0.07
- Sarbajeet Nagdas · 1 shared paper, 2018 · strength 0.07
- Matthew H. G. Katz · 1 shared paper, 2015 · strength 0.05
- Gauri Rajani Varadhachary · 1 shared paper, 2015 · strength 0.05
- Osama E. Rahma · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.